132 related articles for article (PubMed ID: 1428914)
21. Reliability of a simple non-invasive method for the evaluation of 5-HT2 receptors using [18F]-setoperone PET imaging.
Kapur S; Jones C; DaSilva J; Wilson A; Houle S
Nucl Med Commun; 1997 May; 18(5):395-9. PubMed ID: 9194079
[TBL] [Abstract][Full Text] [Related]
22. Where have we got to with neuroreceptor mapping of the human brain?
Mazière B; Mazière M
Eur J Nucl Med; 1990; 16(11):817-35. PubMed ID: 2170141
[TBL] [Abstract][Full Text] [Related]
23. Quantitative in vitro phosphor imaging using [3H] and [18F] radioligands: the effects of chronic desipramine treatment on serotonin 5-HT2 receptors.
Strome EM; Jivan S; Doudet DJ
J Neurosci Methods; 2005 Jan; 141(1):143-54. PubMed ID: 15585298
[TBL] [Abstract][Full Text] [Related]
24. 5-HT1 and 5-HT2 binding profiles of the serotonergic agents alpha-methylserotonin and 2-methylserotonin.
Ismaiel AM; Titeler M; Miller KJ; Smith TS; Glennon RA
J Med Chem; 1990 Feb; 33(2):755-8. PubMed ID: 2299641
[TBL] [Abstract][Full Text] [Related]
25. Radiosynthesis of [18F]Lu29-024: a potential PET ligand for brain imaging of the serotonergic 5-HT2 receptor.
Sobrio F; Amokhtari M; Gourand F; Dhilly M; Dauphin F; Barré L
Bioorg Med Chem; 2000 Oct; 8(10):2511-8. PubMed ID: 11058046
[TBL] [Abstract][Full Text] [Related]
26. Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding.
Hoyer D; Neijt HC
Mol Pharmacol; 1988 Mar; 33(3):303-9. PubMed ID: 3352595
[TBL] [Abstract][Full Text] [Related]
27. Imaging the 5-HT(1A) receptors with PET: WAY-100635 and analogues.
Houle S; DaSilva JN; Wilson AA
Nucl Med Biol; 2000 Jul; 27(5):463-6. PubMed ID: 10962251
[TBL] [Abstract][Full Text] [Related]
28. Blood-cerebrospinal fluid and blood-brain barriers imaged by 18F-labeled metabolites of 18F-setoperone studied in humans using positron emission tomography.
Blin J; Crouzel C
J Neurochem; 1992 Jun; 58(6):2303-10. PubMed ID: 1573409
[TBL] [Abstract][Full Text] [Related]
29. Classification of serotonin receptors.
Göthert M; Schlicker E
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S3-7. PubMed ID: 2446065
[TBL] [Abstract][Full Text] [Related]
30. PET radioligands for dopamine receptors and re-uptake sites: chemistry and biochemistry.
Mazière B; Coenen HH; Halldin C; Någren K; Pike VW
Int J Rad Appl Instrum B; 1992 May; 19(4):497-512. PubMed ID: 1526814
[TBL] [Abstract][Full Text] [Related]
31. Radiosynthesis and in vivo evaluation of novel radioligands for PET imaging of cerebral 5-HT7 receptors.
Hansen HD; Herth MM; Ettrup A; Andersen VL; Lehel S; Dyssegaard A; Kristensen JL; Knudsen GM
J Nucl Med; 2014 Apr; 55(4):640-6. PubMed ID: 24566002
[TBL] [Abstract][Full Text] [Related]
32. Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach.
Pinborg LH; Adams KH; Svarer C; Holm S; Hasselbalch SG; Haugbøl S; Madsen J; Knudsen GM
J Cereb Blood Flow Metab; 2003 Aug; 23(8):985-96. PubMed ID: 12902843
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.
Herth MM; Kramer V; Piel M; Palner M; Riss PJ; Knudsen GM; Rösch F
Bioorg Med Chem; 2009 Apr; 17(8):2989-3002. PubMed ID: 19329329
[TBL] [Abstract][Full Text] [Related]
34. Characterization of 3H-serotonin (5-HT) binding and effects on the phosphoinositides (PI) turnover in cultured C6 glioma and N2 neuroblastoma cells from rodents.
Wei JW; Yeh SR; Cheng CL
Chin J Physiol; 1992; 35(3):227-39. PubMed ID: 1338307
[TBL] [Abstract][Full Text] [Related]
35. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site.
Pazos A; Hoyer D; Palacios JM
Eur J Pharmacol; 1984 Nov; 106(3):539-46. PubMed ID: 6519175
[TBL] [Abstract][Full Text] [Related]
36. Parametric PET imaging of 5HT2A receptor distribution with 18F-setoperone in the normal human neocortex.
Petit-Taboué MC; Landeau B; Barré L; Onfroy MC; Noël MH; Baron JC
J Nucl Med; 1999 Jan; 40(1):25-32. PubMed ID: 9935052
[TBL] [Abstract][Full Text] [Related]
37. Central serotonergic receptors: evidence for heterogeneity and characterization by ligand-binding.
Nelson DL
Neurosci Biobehav Rev; 1982; 6(4):499-502. PubMed ID: 6757812
[TBL] [Abstract][Full Text] [Related]
38. Quantification of 5-HT(1A) receptors in human brain using p-MPPF kinetic modelling and PET.
Sanabria-Bohórquez SM; Biver F; Damhaut P; Wikler D; Veraart C; Goldman S
Eur J Nucl Med Mol Imaging; 2002 Jan; 29(1):76-81. PubMed ID: 11807610
[TBL] [Abstract][Full Text] [Related]
39. Physiological, pathophysiological and therapeutic impact of the enteric serotonergic system.
Molderings GJ
Arzneimittelforschung; 2012 Apr; 62(4):157-66. PubMed ID: 22438071
[TBL] [Abstract][Full Text] [Related]
40. PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin.
van Dyck CH; Tan PZ; Baldwin RM; Amici LA; Garg PK; Ng CK; Soufer R; Charney DS; Innis RB
J Nucl Med; 2000 Feb; 41(2):234-41. PubMed ID: 10688105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
